Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medicBluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that positive results of analytical and clinical studies of Bluejay’s Symphony IL-6 Test were presented at AACC 2022, the leading industry conference for clinical laboratory medicine.

More details.